<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0119476</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-47001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">p53 Status and NMIBC Treated with BCG</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhou</surname>
<given-names>Xiaofeng</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Guan</given-names>
</name>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Tian</surname>
<given-names>Ye</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Urology, Beijing Friendship Hospital, Capital Medical University, Yongan Road 95, Beijing 100050, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Urology, China-Japan Friendship Hospital, Yinghua East Road 2, Beijing 100029, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Seno</surname>
<given-names>Masaharu</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Okayama University, JAPAN</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: YT. Performed the experiments: XFZ YT. Analyzed the data: GZ. Contributed reagents/materials/analysis tools: YT GZ. Wrote the paper: XFZ YT.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">dr_tianye@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>5</day>
<month>3</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<elocation-id>e0119476</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>10</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>1</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Zhou et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0119476" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>Published studies have yielded inconsistent results on the relationship between p53 status and the prognosis of non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Therefore, we performed a meta-analysis to evaluate the prognostic value of p53 in NMIBC treated with BCG.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>We systematically searched for relevant literature in PubMed, EMBASE, CNKI, and Chinese Wanfang databases. Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined as the effect size (ES) across studies for recurrence-free survival (RFS) and progression-free survival (PFS).</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of 11 studies, consisting of 1,049 participants, met the criteria. Overall, there was no clear relationship between p53 status and RFS or PFS for NMIBC patients treated with BCG (HR: 1.40, 95% CI: 0.91-2.16; HR: 1.37, 95% CI: 0.90-2.09, respectively). Obvious heterogeneity was observed across the studies (I<sup>2</sup> = 69.5%, <italic>P</italic> = 0.001; I<sup>2</sup> = 44.7%, <italic>P</italic> = 0.081, respectively). In stratified analysis by region, p53 overexpression was a predictor of poor RFS in Asian populations (HR: 1.57, 95% CI: 1.08-2.27). In addition, after excluding the studies that possibly contributed to the heterogeneity by the Galbraith plot, the overall association for RFS became statistically significant (HR: 1.38 95% CI: 1.08-1.77) without evidence of heterogeneity (I<sup>2</sup> = 0.0%, <italic>P</italic> = 0.499).</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>This meta-analysis suggests that p53 overexpression in NMIBC patients treated with BCG may be associated with RFS, especially in Asian populations. Because of the heterogeneity and other limitations, further studies with rigid criteria and large populations are still warranted to confirm our findings.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81373637) and International S&amp;T Cooperation Program of China (ISTCP) (Grant No. 2014DFE30010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Bladder cancer ranks ninth in the worldwide cancer incidence [<xref rid="pone.0119476.ref001" ref-type="bibr">1</xref>]. There were a total of 386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 [<xref rid="pone.0119476.ref002" ref-type="bibr">2</xref>]. Among these, approximately 70% of bladder tumors are non-muscle invasive bladder cancers (NMIBCs) at the time of presentation [<xref rid="pone.0119476.ref003" ref-type="bibr">3</xref>]. Recently, after initial transurethral resection of bladder tumors (TURB), adjuvant intravesical treatment with Bacillus Calmette–Guérin (BCG) was selected as the first-line therapy for patients with NMIBC. However, predicting which patients are destined to fail BCG treatment is still a very difficult task [<xref rid="pone.0119476.ref004" ref-type="bibr">4</xref>].</p>
<p>Molecular tumor markers hold considerable promise for accurately predicting the recurrence and progression of NMIBC patients treated with BCG intravesical therapy. Deregulation of the cell-cycle machinery is common in bladder cancer, involving alterations in various proteins such as cyclin D1, Rb, p16, p21, p27, and p53 [<xref rid="pone.0119476.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0119476.ref006" ref-type="bibr">6</xref>]. The value of pretreatment p53 overexpression on the prognosis of NMIBC patients treated with BCG has been widely studied and discussed. As a result, most of reports are in consensus that p53 is not associated with the prognosis [<xref rid="pone.0119476.ref007" ref-type="bibr">7</xref>–<xref rid="pone.0119476.ref011" ref-type="bibr">11</xref>]. However, several studies have suggested different results. For example, three independent studies reported a positive association between strong p53 overexpression and the risk of recurrence in NMIBC patients treated with intravesical BCG [<xref rid="pone.0119476.ref012" ref-type="bibr">12</xref>–<xref rid="pone.0119476.ref014" ref-type="bibr">14</xref>], whereas Oderda et al.’ study suggested a negative association between them [<xref rid="pone.0119476.ref015" ref-type="bibr">15</xref>]. In addition, studies conducted by Lopez-Beltran et al. and Lacombe et al. indicated that increased p53 expression was associated with the risk of progression [<xref rid="pone.0119476.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0119476.ref017" ref-type="bibr">17</xref>].</p>
<p>Meta-analysis is a useful method for overcoming the small sample size problem of individual studies and enhancing the low statistical power [<xref rid="pone.0119476.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0119476.ref019" ref-type="bibr">19</xref>]. Considering the inconsistent results of published articles, we performed a comprehensive meta-analysis of all published studies to determine the value of p53 as a prognostic marker for NMIBC patients treated with BCG intravesical instillations.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Search strategy</title>
<p>This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [<xref rid="pone.0119476.ref020" ref-type="bibr">20</xref>] (<xref rid="pone.0119476.s001" ref-type="supplementary-material">S1 PRISMA Checklist</xref>). Published articles studying the prognostic value of p53 in NMIBC treated with BCG were identified from PubMed, EMBASE, CNKI, and Chinese Wanfang databases with the following search terms: “bladder cancer or bladder carcinoma or bladder neoplasm or bladder tumor”, “Bacillus Calmette–Guérin or BCG”, and “p53 or TP53”. The final search was conducted on November 30, 2014. The references of the retrieved articles and reviews were also screened for additional relevant studies. The eligible publications were selected by two reviewers, and controversial articles were adjudicated by a third reviewer.</p>
</sec>
<sec id="sec008">
<title>Inclusion criteria</title>
<p>The following criteria were applied to identify the eligible articles: (a) to evaluate the relationship between p53 status and the prognosis of NMIBC patients treated with BCG; (b) to detect p53 status in the primary tumor tissues using immunohistochemistry (IHC); (c) to provide adequate data to estimate the hazard ratios (HRs) and their 95% confidence intervals (CIs); and (d) publications in English or Chinese. For overlapping studies, the most recent and detailed study was eligible for inclusion in this meta-analysis.</p>
</sec>
<sec id="sec009">
<title>Data extraction</title>
<p>According to the inclusion criteria listed above, two reviewers independently extracted the following information: the first author’s surname, publication year, country in which the study was conducted, number of patients analyzed, age of the patients, follow-up time, disease stage, cut-off value, and prognostic data. Disagreement was resolved by a consensus discussion among all authors.</p>
</sec>
<sec id="sec010">
<title>Statistical methods</title>
<p>The impact of p53 expression on survival was quantified with the combined HRs and 95% CIs. The HR and 95% CI of each study were directly extracted from each publication. If not directly available, they were calculated from the available data in the articles using methods described by Parmar et al. [<xref rid="pone.0119476.ref021" ref-type="bibr">21</xref>]. In this meta-analysis, the DerSimonian–Laird random-effect model [<xref rid="pone.0119476.ref022" ref-type="bibr">22</xref>] was applied, which considered both within-study and between-study variation. By convention, an HR &gt; 1 corresponded to a poor outcome for increased p53, while HR &lt; 1 indicated a favorable prognosis. The impact of increased p53 expression on survival was considered statistically significant if the 95% CI did not exceed 1. Subgroup analyses by different analytical methods (region, sample size, follow-up time, stage, cut-off, publication year, and patient age) were performed. We also performed a cumulative meta-analysis by sorting the studies according to the publication year [<xref rid="pone.0119476.ref023" ref-type="bibr">23</xref>].</p>
<p>Statistical heterogeneity across studies was assessed by the Chi-square-based Q test and I<sup>2</sup> statistic [<xref rid="pone.0119476.ref024" ref-type="bibr">24</xref>]. A <italic>P</italic> value &lt; 0.10 was considered statistically significant. The value of I<sup>2</sup> was used to evaluate the degree of heterogeneity (no heterogeneity: I<sup>2</sup> &lt; 25%; moderate heterogeneity: I<sup>2</sup> = 25–50%; and large or extreme heterogeneity: I<sup>2</sup> &gt; 50%). In addition, the Galbraith plot was used to detect the possible sources of heterogeneity [<xref rid="pone.0119476.ref025" ref-type="bibr">25</xref>], and a re-analysis was conducted after excluding the studies that possibly contributed to the heterogeneity. Additionally, residual maximum likelihood (REML)-based random-effects meta-regression analysis was used to explore the potential sources of heterogeneity [<xref rid="pone.0119476.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0119476.ref027" ref-type="bibr">27</xref>].</p>
</sec>
<sec id="sec011">
<title>Estimation of the publication bias</title>
<p>The potential publication bias was estimated using Begg’s funnel plot [<xref rid="pone.0119476.ref028" ref-type="bibr">28</xref>], Egger’s test [<xref rid="pone.0119476.ref029" ref-type="bibr">29</xref>], and the trim-and-fill method [<xref rid="pone.0119476.ref030" ref-type="bibr">30</xref>]. <italic>P</italic> &lt; 0.05 was considered representative of a statistically significant publication bias. All of the statistical analyses were performed with STATA 11.0 (StataCorp, College Station, Texas USA) using two-sided <italic>P</italic> values.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Study selection</title>
<p>As shown in <xref rid="pone.0119476.g001" ref-type="fig">Fig. 1</xref>, a total of 187 articles were identified using the search strategy as described above. After carefully reading the titles and abstracts, 166 studies that were not relevant to our aim were excluded. Upon further review of the remaining 21 articles, 3 were excluded because not all of the included patients were treated with BCG, 3 were excluded because they did not provide sufficient data to calculate the HR, 3 were excluded because they did not include survival analysis, and 1 was excluded because it had data that overlapped with other studies. After selection, a total of 11 articles were finally included in the evaluation of the prognostic value of p53 status in NMIBC patients treated with BCG.</p>
<fig id="pone.0119476.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flowchart of study selection.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.g001" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec014">
<title>Characteristics of the eligible studies</title>
<p>The clinical features of these 11 eligible studies are summarized in <xref rid="pone.0119476.t001" ref-type="table">Table 1</xref>. These studies were published between 1996 and 2013. Three articles evaluated patients from Korea, 2 from Italy, 2 from France, 1 from the USA, 1 from Singapore, 1 from Spain, and 1 from two countries (Netherlands and Canada). The total number of patients was 1,049, with study sample sizes ranging from 27 to 275 patients. The follow-up period was at least 24 months and the follow-up period for 5 studies was at least 60 months. The definition of the cut-off value for high p53 expression was varied and 6 studies used the percentage of stained cells not less than 20%. The HRs and 95% CIs were recorded for each study using reported data or the methods described above. Recurrence-free survival (RFS) was reported in 9 studies and progression-free survival (PFS) reported in 8 studies.</p>
<table-wrap id="pone.0119476.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.t001</object-id>
<label>Table 1</label> <caption><title>Main characteristics of all studies included in this meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0119476.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Study</th>
<th align="left" rowspan="1" colspan="1">Year</th>
<th align="left" rowspan="1" colspan="1">Country</th>
<th align="left" rowspan="1" colspan="1">No. of Patients</th>
<th align="left" rowspan="1" colspan="1">Age (years)</th>
<th align="left" rowspan="1" colspan="1">Follow up (months)</th>
<th align="left" rowspan="1" colspan="1">Stage</th>
<th align="left" rowspan="1" colspan="1">Cut off</th>
<th align="left" rowspan="1" colspan="1">Survival analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Oderda et al</td>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">192</td>
<td align="left" rowspan="1" colspan="1">73.2 (SD 11.9)</td>
<td align="left" rowspan="1" colspan="1">100 (2–229)</td>
<td align="left" rowspan="1" colspan="1">All NMIBC</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Park et al</td>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="left" rowspan="1" colspan="1">Korea</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">66 (31–85)</td>
<td align="left" rowspan="1" colspan="1">60 (6–217)</td>
<td align="left" rowspan="1" colspan="1">T1G3</td>
<td align="left" rowspan="1" colspan="1">10%</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">van Rhijn et al</td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Netherlands,Canada</td>
<td align="left" rowspan="1" colspan="1">129</td>
<td align="left" rowspan="1" colspan="1">68.8 (SD 9.9)</td>
<td align="left" rowspan="1" colspan="1">78 (39.6–110.4)</td>
<td align="left" rowspan="1" colspan="1">T1</td>
<td align="left" rowspan="1" colspan="1">10%</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Oh et al</td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Korea</td>
<td align="left" rowspan="1" colspan="1">275</td>
<td align="left" rowspan="1" colspan="1">63.9</td>
<td align="left" rowspan="1" colspan="1">50.4 (0–115.2)</td>
<td align="left" rowspan="1" colspan="1">All NMIBC</td>
<td align="left" rowspan="1" colspan="1">60%</td>
<td align="left" rowspan="1" colspan="1">RFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cormio et al</td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">27</td>
<td align="left" rowspan="1" colspan="1">69 (57–81)</td>
<td align="left" rowspan="1" colspan="1">60 (15–135)</td>
<td align="left" rowspan="1" colspan="1">T1G3</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Esuvaranathan et al</td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">Singapore</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">63.5</td>
<td align="left" rowspan="1" colspan="1">54 (6–114)</td>
<td align="left" rowspan="1" colspan="1">All NMIBC</td>
<td align="left" rowspan="1" colspan="1">Score &gt; 3</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lopez-Beltran et al</td>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="left" rowspan="1" colspan="1">Spain</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">69.96 (49–89)</td>
<td align="left" rowspan="1" colspan="1">63.82 (60–144)</td>
<td align="left" rowspan="1" colspan="1">T1G3</td>
<td align="left" rowspan="1" colspan="1">6%</td>
<td align="left" rowspan="1" colspan="1">PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Saint et al</td>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="left" rowspan="1" colspan="1">France</td>
<td align="left" rowspan="1" colspan="1">102</td>
<td align="left" rowspan="1" colspan="1">64.6 (36.8–88)</td>
<td align="left" rowspan="1" colspan="1">40 (4.4–164.5)</td>
<td align="left" rowspan="1" colspan="1">All NMIBC</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">RFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Peyromaure et al</td>
<td align="left" rowspan="1" colspan="1">2002</td>
<td align="left" rowspan="1" colspan="1">France</td>
<td align="left" rowspan="1" colspan="1">29</td>
<td align="left" rowspan="1" colspan="1">72.2 (52–87)</td>
<td align="left" rowspan="1" colspan="1">36.7 (1–108)</td>
<td align="left" rowspan="1" colspan="1">T1G3</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">RFS,PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee et al</td>
<td align="left" rowspan="1" colspan="1">1997</td>
<td align="left" rowspan="1" colspan="1">Korea</td>
<td align="left" rowspan="1" colspan="1">32</td>
<td align="left" rowspan="1" colspan="1">57.1 (30–81)</td>
<td align="left" rowspan="1" colspan="1">All &gt; 24</td>
<td align="left" rowspan="1" colspan="1">T1G2–3</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">RFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lacombe et al</td>
<td align="left" rowspan="1" colspan="1">1996</td>
<td align="left" rowspan="1" colspan="1">USA</td>
<td align="left" rowspan="1" colspan="1">98</td>
<td align="left" rowspan="1" colspan="1">65 (28–83)</td>
<td align="left" rowspan="1" colspan="1">44 (2–66)</td>
<td align="left" rowspan="1" colspan="1">All NMIBC</td>
<td align="left" rowspan="1" colspan="1">20%</td>
<td align="left" rowspan="1" colspan="1">PFS</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>No., number; NMIBC, non-muscle-invasive bladder cancer; RFS, recurrence-free survival; PFS, progression-free survival.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec015">
<title>Impact of p53 expression on RFS</title>
<p>Nine articles contained information on the correlation between p53 expression and RFS in NMIBC patients treated with BCG. The combined data from all these studies suggested that p53 overexpression was not statistically associated with RFS with a pooled HR estimate of 1.40 (95% CI: 0.91–2.16) (<xref rid="pone.0119476.g002" ref-type="fig">Fig. 2A</xref>). Obvious heterogeneity was observed (I<sup>2</sup> = 69.5%, <italic>P</italic> = 0.001). However, subgroup analysis by region showed that increased p53 expression was significantly correlated with RFS in Asian populations (HR: 1.57, 95% CI: 1.08–2.27), and there was no significant heterogeneity across the studies (I<sup>2</sup> = 10.7%, <italic>P</italic> = 0.339). Likewise, stratification analysis by patient age indicated that p53 was also significantly associated with RFS in patients ≤ 65 years old (HR: 2.43, 95% CI: 1.16–5.12), which had significant heterogeneity (I<sup>2</sup> = 70.2%, <italic>P</italic> = 0.018) (<xref rid="pone.0119476.t002" ref-type="table">Table 2</xref>)</p>
<fig id="pone.0119476.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plots of HRs estimated for the relationship between p53 expression and RFS (A) or PFS (B) among NMIBC patients treated with BCG.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.g002" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0119476.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.t002</object-id>
<label>Table 2</label> <caption><title>Subgroup results of RFS and heterogeneity test.</title></caption>
<alternatives>
<graphic id="pone.0119476.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="3" align="center" rowspan="1"/>
<th colspan="3" align="center" rowspan="1">Heterogeneity test</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Variables</th>
<th align="left" rowspan="1" colspan="1">Study number</th>
<th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
<th align="left" rowspan="1" colspan="1">Q</th>
<th align="left" rowspan="1" colspan="1"><italic>P</italic></th>
<th align="left" rowspan="1" colspan="1">I<sup>2</sup> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Total RFS</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">1.40 (0.91–2.16)</td>
<td align="char" char="." rowspan="1" colspan="1">26.20</td>
<td align="char" char="." rowspan="1" colspan="1">0.001</td>
<td align="char" char="." rowspan="1" colspan="1">69.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Region</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Asian</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.57 (1.08–2.27)</td>
<td align="char" char="." rowspan="1" colspan="1">3.36</td>
<td align="char" char="." rowspan="1" colspan="1">0.339</td>
<td align="char" char="." rowspan="1" colspan="1">10.7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Caucasian</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.28 (0.62–2.67)</td>
<td align="char" char="." rowspan="1" colspan="1">19.99</td>
<td align="char" char="." rowspan="1" colspan="1">0.001</td>
<td align="char" char="." rowspan="1" colspan="1">80.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sample size</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 100</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.50 (0.76–2.95)</td>
<td align="char" char="." rowspan="1" colspan="1">21.26</td>
<td align="char" char="." rowspan="1" colspan="1">&lt; 0.001</td>
<td align="char" char="." rowspan="1" colspan="1">85.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 100</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.33 (0.78–2.24)</td>
<td align="char" char="." rowspan="1" colspan="1">4.89</td>
<td align="char" char="." rowspan="1" colspan="1">0.299</td>
<td align="char" char="." rowspan="1" colspan="1">18.2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Follow-up (months)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 60</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.94 (0.61–1.46)</td>
<td align="char" char="." rowspan="1" colspan="1">5.30</td>
<td align="char" char="." rowspan="1" colspan="1">0.151</td>
<td align="char" char="." rowspan="1" colspan="1">43.4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 60</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.75 (0.81–3.75)</td>
<td align="char" char="." rowspan="1" colspan="1">10.43</td>
<td align="char" char="." rowspan="1" colspan="1">0.015</td>
<td align="char" char="." rowspan="1" colspan="1">71.2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> All NMIBC</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.54 (0.67–3.52)</td>
<td align="char" char="." rowspan="1" colspan="1">21.26</td>
<td align="char" char="." rowspan="1" colspan="1">&lt; 0.001</td>
<td align="char" char="." rowspan="1" colspan="1">85.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> T1G3</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.98 (0.52–1.83)</td>
<td align="char" char="." rowspan="1" colspan="1">0.33</td>
<td align="char" char="." rowspan="1" colspan="1">0.849</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cut-off</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> 20%</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.62 (0.58–4.50)</td>
<td align="char" char="." rowspan="1" colspan="1">24.59</td>
<td align="char" char="." rowspan="1" colspan="1">&lt; 0.001</td>
<td align="char" char="." rowspan="1" colspan="1">83.7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Others</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.37 (1.05–1.78)</td>
<td align="char" char="." rowspan="1" colspan="1">0.70</td>
<td align="char" char="." rowspan="1" colspan="1">0.872</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Publication year</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 2009</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.09(0.73–1.61)</td>
<td align="char" char="." rowspan="1" colspan="1">9.18</td>
<td align="char" char="." rowspan="1" colspan="1">0.057</td>
<td align="char" char="." rowspan="1" colspan="1">56.4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 2009</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">2.20(0.81–5.94)</td>
<td align="char" char="." rowspan="1" colspan="1">11.14</td>
<td align="char" char="." rowspan="1" colspan="1">0.011</td>
<td align="char" char="." rowspan="1" colspan="1">73.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Patient age (years)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &gt; 65</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.92(0.64–1.33)</td>
<td align="char" char="." rowspan="1" colspan="1">5.45</td>
<td align="char" char="." rowspan="1" colspan="1">0.245</td>
<td align="char" char="." rowspan="1" colspan="1">26.6</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≤ 65</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">2.43(1.16–5.12)</td>
<td align="char" char="." rowspan="1" colspan="1">10.06</td>
<td align="char" char="." rowspan="1" colspan="1">0.018</td>
<td align="char" char="." rowspan="1" colspan="1">70.2</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec016">
<title>Impact of p53 expression on PFS</title>
<p>The relationship between p53 expression and PFS in NMIBC patients treated with BCG is illustrated in <xref rid="pone.0119476.g002" ref-type="fig">Fig. 2B</xref>. The pooled HR for all 8 articles was 1.37 (95% CI: 0.90–2.09), which had significant heterogeneity (I<sup>2</sup> = 44.7%, <italic>P</italic> = 0.081). In the stratified analyses by the region, sample size, follow-up time, stage, cut-off, publication year, and patient age, significant associations were only observed in the studies with sample sizes smaller than 100, follow-up shorter than 60 months, and patient age ≤ 65 years (HR: 1.97, 95% CI: 1.04–3.74; HR: 2.37, 95% CI: 1.23–4.55; HR: 2.49, 95% CI: 1.19–5.21, respectively) (<xref rid="pone.0119476.t003" ref-type="table">Table 3</xref>).</p>
<table-wrap id="pone.0119476.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.t003</object-id>
<label>Table 3</label> <caption><title>Subgroup results of PFS and heterogeneity test.</title></caption>
<alternatives>
<graphic id="pone.0119476.t003g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.t003" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="3" align="center" rowspan="1"/>
<th colspan="3" align="center" rowspan="1">Heterogeneity test</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Variables</th>
<th align="left" rowspan="1" colspan="1">Study number</th>
<th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
<th align="left" rowspan="1" colspan="1">Q</th>
<th align="left" rowspan="1" colspan="1"><italic>P</italic></th>
<th align="left" rowspan="1" colspan="1">I<sup>2</sup> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Total PFS</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">1.37 (0.90–2.09)</td>
<td align="char" char="." rowspan="1" colspan="1">12.65</td>
<td align="char" char="." rowspan="1" colspan="1">0.081</td>
<td align="char" char="." rowspan="1" colspan="1">44.7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Region</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Asian</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">3.13 (0.83–11.80)</td>
<td align="char" char="." rowspan="1" colspan="1">0.15</td>
<td align="char" char="." rowspan="1" colspan="1">0.703</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Caucasian</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.26 (0.81–1.95)</td>
<td align="char" char="." rowspan="1" colspan="1">9.84</td>
<td align="char" char="." rowspan="1" colspan="1">0.080</td>
<td align="char" char="." rowspan="1" colspan="1">49.2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sample size</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 100</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.78 (0.43–1.42)</td>
<td align="char" char="." rowspan="1" colspan="1">0.22</td>
<td align="char" char="." rowspan="1" colspan="1">0.637</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 100</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.97 (1.04–3.74)</td>
<td align="char" char="." rowspan="1" colspan="1">11.52</td>
<td align="char" char="." rowspan="1" colspan="1">0.042</td>
<td align="char" char="." rowspan="1" colspan="1">56.6</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Follow-up (months)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 60</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.10 (0.70–1.72)</td>
<td align="char" char="." rowspan="1" colspan="1">6.47</td>
<td align="char" char="." rowspan="1" colspan="1">0.166</td>
<td align="char" char="." rowspan="1" colspan="1">38.2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 60</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">2.37 (1.23–4.55)</td>
<td align="char" char="." rowspan="1" colspan="1">0.09</td>
<td align="char" char="." rowspan="1" colspan="1">0.956</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> All NMIBC</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">1.58 (0.60–4.12)</td>
<td align="char" char="." rowspan="1" colspan="1">3.61</td>
<td align="char" char="." rowspan="1" colspan="1">0.164</td>
<td align="char" char="." rowspan="1" colspan="1">44.7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> T1G3</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.86 (0.80–4.34)</td>
<td align="char" char="." rowspan="1" colspan="1">6.11</td>
<td align="char" char="." rowspan="1" colspan="1">0.106</td>
<td align="char" char="." rowspan="1" colspan="1">50.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cut-off</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> 20%</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.89 (0.84–4.25)</td>
<td align="char" char="." rowspan="1" colspan="1">4.98</td>
<td align="char" char="." rowspan="1" colspan="1">0.173</td>
<td align="char" char="." rowspan="1" colspan="1">39.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> Others</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.04 (0.87–1.25)</td>
<td align="char" char="." rowspan="1" colspan="1">3.20</td>
<td align="char" char="." rowspan="1" colspan="1">0.362</td>
<td align="char" char="." rowspan="1" colspan="1">6.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Publication year</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≥ 2009</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.41(0.54–3.70)</td>
<td align="char" char="." rowspan="1" colspan="1">6.46</td>
<td align="char" char="." rowspan="1" colspan="1">0.091</td>
<td align="char" char="." rowspan="1" colspan="1">53.6</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &lt; 2009</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.53(0.85–2.78)</td>
<td align="char" char="." rowspan="1" colspan="1">6.18</td>
<td align="char" char="." rowspan="1" colspan="1">0.103</td>
<td align="char" char="." rowspan="1" colspan="1">51.4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Patient age (years)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> &gt; 65</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.13(0.76–1.68)</td>
<td align="char" char="." rowspan="1" colspan="1">7.23</td>
<td align="char" char="." rowspan="1" colspan="1">0.204</td>
<td align="char" char="." rowspan="1" colspan="1">30.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"> ≤ 65</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">2.49(1.19–5.21)</td>
<td align="char" char="." rowspan="1" colspan="1">0.00</td>
<td align="char" char="." rowspan="1" colspan="1">0.984</td>
<td align="char" char="." rowspan="1" colspan="1">0.0</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec017">
<title>Galbraith plot and meta-regression</title>
<p>Through the Galbraith plot, the studies performed by Saint et al. [<xref rid="pone.0119476.ref012" ref-type="bibr">12</xref>] and Oderda et al. [<xref rid="pone.0119476.ref015" ref-type="bibr">15</xref>] were detected as the major sources of heterogeneity for RFS (<xref rid="pone.0119476.g003" ref-type="fig">Fig. 3A</xref>). After excluding these 2 studies, there was no evidence of heterogeneity across the remaining studies (I<sup>2</sup> = 0.0%, <italic>P</italic> = 0.499) and the overall association became statistically significant (HR: 1.38, 95% CI: 1.08–1.77). Furthermore, the Galbraith plot suggested that the study conducted by Lacombe et al. [<xref rid="pone.0119476.ref017" ref-type="bibr">17</xref>] contributed to the heterogeneity for PFS (<xref rid="pone.0119476.g003" ref-type="fig">Fig. 3B</xref>). After excluding this study, the pooled HR for the remaining 7 studies was 1.15 (95% CI: 0.79–1.68) and heterogeneity was obviously reduced (I<sup>2</sup> = 25.7%, <italic>P</italic> = 0.233). Furthermore, seven factors (publication year, region, sample size, stage, cut-off, patient age, and follow-up time), which may contribute to the heterogeneity, were assessed by meta-regression. As a result, only the patient age was identified as a possible source of heterogeneity for RFS (<italic>P</italic> = 0.05).</p>
<fig id="pone.0119476.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Galbraith plot analysis was used to evaluate heterogeneity.</title>
<p>It suggested that two studies were the potential source of heterogeneity for RFS (A), while one for PFS (B).</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.g003" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec018">
<title>Cumulative meta-analysis</title>
<p>Cumulative meta-analysis, in the order of the publication time, was conducted. <xref rid="pone.0119476.s002" ref-type="supplementary-material">S1 Fig</xref>. shows the results from the cumulative meta-analysis of the association between p53 and RFS or PFS, which are given in chronologic order. The 95% confidence intervals gradually narrowed with the increasing number of included studies, suggesting that the precision of the summary estimates was progressively boosted by continually enrolling more cases.</p>
</sec>
<sec id="sec019">
<title>Publication bias</title>
<p>In the present meta-analysis, using Begg’s and Egger’s tests, there was no evidence of significant publication bias among the studies with respect to RFS (<italic>P</italic> = 0.754, 0.488) or PFS (<italic>P</italic> = 0.174, 0.110) (<xref rid="pone.0119476.g004" ref-type="fig">Fig. 4</xref>). In addition, the trim-and-fill method suggested that there was no significant change after trimming and filling (data not shown).</p>
<fig id="pone.0119476.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0119476.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Funnel plots of p53 expression and RFS (A) or PFS (B).</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0119476.g004" position="float" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec020" sec-type="conclusions">
<title>Discussion</title>
<p>The current meta-analysis summarizes the results of the published data, which are based on a total of 11 studies (including over 1,000 cancer cases). To the best of our knowledge, this is the first meta-analysis to evaluate the relationship between p53 status and the prognosis of NMIBC patients treated with BCG. The results suggested that overall there was no clear relationship between them. However, in stratified analysis by region, overexpression of p53 was a predictor of poor RFS in Asian populations. This finding suggested that the ethnicity or geographic settings might play an important role in the impact of p53 overexpression on the prognosis of NMIBC patients who undergo BCG treatment after initial TURB.</p>
<p>The Galbraith plot suggested that the observed heterogeneity among the studies of p53 status and RFS could be explained by the studies conducted by Saint et al. [<xref rid="pone.0119476.ref012" ref-type="bibr">12</xref>] and Oderda et al. [<xref rid="pone.0119476.ref015" ref-type="bibr">15</xref>]. These studies reported the strongest positive and negative relationships (HR: 6.67, 95% CI: 2.38–16.67; HR: 0.61, 95% CI: 0.38–0.98, respectively). After excluding these 2 studies, the association between p53 overexpression and RFS in NMIBC patients treated with BCG became significant (HR: 1.38, 95% CI: 1.08–1.77) without any evidence of study heterogeneity (I<sup>2</sup> = 0.0%, <italic>P</italic> = 0.499). These results suggested that the heterogeneity across the included studies might have led to an underestimation of the risk estimate for RFS, and p53 was likely to be a potential predictor of RFS.</p>
<p>The prognosis of NMIBC, also called superficial bladder cancer, is heterogeneous and clinical treatments vary considerably between patients [<xref rid="pone.0119476.ref031" ref-type="bibr">31</xref>–<xref rid="pone.0119476.ref033" ref-type="bibr">33</xref>]. According to the recommendations of the 2013 European Association of Urology (EAU) guidelines, the risks of both recurrence and progression could be estimated for individual patients by applying the European Organization for Research and Treatment of Cancer (EORTC) scoring system, which incorporates the following six most important clinical and pathologic factors: tumor number, grade, size, prior recurrence rate, T category, and concomitant carcinoma in situ (CIS). Using the above characteristics, patients can be divided into several risk groups with different adjuvant therapy, either chemotherapy or immunotherapy with BCG [<xref rid="pone.0119476.ref034" ref-type="bibr">34</xref>]. In addition, the Spanish Urological Club for Oncological Treatment (CUETO) scoring model was developed for BCG-treated patients to predict the short- and long-term probabilities of recurrence and progression and the discrimination was superior to EORTC in BCG-treated patients [<xref rid="pone.0119476.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0119476.ref035" ref-type="bibr">35</xref>]. However, accurately predicting which NMIBC patients will experience recurrence or progression to muscle-invasive disease is still very difficult [<xref rid="pone.0119476.ref036" ref-type="bibr">36</xref>]. Therefore, there is a need for new and reliable prognostic factors.</p>
<p>In human cancers, p53 is the most commonly inactivated tumor suppressor gene [<xref rid="pone.0119476.ref037" ref-type="bibr">37</xref>]. Loss of expression of wild-type p53 contributes to abnormal cell proliferation and tumorigenesis, while mutant p53 can gain new abilities promoting cell migration, invasion and metastasis, which are partially from interference with p63 function [<xref rid="pone.0119476.ref038" ref-type="bibr">38</xref>]. Many IHC studies have confirmed that p53 is highly overexpressed in bladder cancer patients and that it is associated with advanced bladder tumor stage and grade [<xref rid="pone.0119476.ref039" ref-type="bibr">39</xref>,<xref rid="pone.0119476.ref040" ref-type="bibr">40</xref>]. Furthermore, p53 overexpression appears to correlate with the mitotic index and vascular invasion [<xref rid="pone.0119476.ref041" ref-type="bibr">41</xref>]. Therefore, p53 is a potential surrogate biomarker for NMIBC patients who are treated with BCG. As mentioned previously, several studies have investigated the influence of p53 overexpression on NMIBC patients who have undergone intravesical BCG treatment after initial TURB. However, the results of these reports are still controversial. As individual studies may have insufficient statistical power, our meta-analysis of 11 studies, involving a great many NMIBC patients, enhanced the statistical power and provided more reliable estimates.</p>
<p>To date, various meta-analyses have evaluated the relationship between p53 and bladder cancer with a focus on other topics. For example, several meta-analyses have assessed the relationship between p53 Arg72Pro polymorphism and bladder cancer risk [<xref rid="pone.0119476.ref042" ref-type="bibr">42</xref>–<xref rid="pone.0119476.ref046" ref-type="bibr">46</xref>]. As a consequence, most of these reported that p53 Arg72Pro polymorphism was associated with an increased risk of bladder cancer in Asians but not in Caucasians [<xref rid="pone.0119476.ref042" ref-type="bibr">42</xref>–<xref rid="pone.0119476.ref045" ref-type="bibr">45</xref>]. This result was similar to our study, which also indicated that the association was more robust in Asians than Caucasians. Therefore, p53 may really have race-specific effects on bladder cancer. With respect to the prognosis, the meta-analysis conducted by Malats et al, which was published in 2005, suggested that the evidence was not sufficient to conclude whether p53 could serve as a marker of the outcome in patients with bladder cancer [<xref rid="pone.0119476.ref047" ref-type="bibr">47</xref>].</p>
<p>Several important limitations should be considered in interpreting the results of our meta-analysis. First, this meta-analysis was limited by the presence of heterogeneity across the studies. The heterogeneity may be from the differences in the characteristics of the patients, technical platforms, cut-off values, and follow-up time. Second, although the Begg’s and Egger’s test did not indicate any evidence of publication bias, the results may have been influenced by publication bias, because only studies published in English and Chinese were searched and included. Finally, there was a wide range of values for the cut-off points for the low and high categories of p53 expression in the included studies, which might also have an impact on the current analysis. Therefore, large cohort studies must be performed in the future with uniform criteria for high p53 expression.</p>
<p>In conclusion, our study suggests that, based on the available information, p53 overexpression in NMIBC patients treated with BCG may be associated with RFS, especially in Asian populations. Because of the limitations discussed above, further studies with rigid criteria and large populations are still warranted to confirm the findings of our study.</p>
</sec>
<sec id="sec021">
<title>Supporting Information</title>
<supplementary-material id="pone.0119476.s001" xlink:href="info:doi/10.1371/journal.pone.0119476.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0119476.s002" xlink:href="info:doi/10.1371/journal.pone.0119476.s002" mimetype="image/tiff" position="float" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Results from cumulative meta-analysis of the association between p53 expression and RFS (A) or PFS (B).</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0119476.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ploeg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aben</surname> <given-names>KK</given-names></name>, <name name-style="western"><surname>Kiemeney</surname> <given-names>LA</given-names></name>. <article-title>The present and future burden of urinary bladder cancer in the world</article-title>. <source>World J Urol</source>. <year>2009</year>; <volume>27</volume>: <fpage>289</fpage>–<lpage>293</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00345-009-0383-3" xlink:type="simple">10.1007/s00345-009-0383-3</ext-link></comment> <object-id pub-id-type="pmid">19219610</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Center</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Ferlay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ward</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Forman</surname> <given-names>D</given-names></name>. <article-title>Global cancer statistics</article-title>. <source>CA Cancer J Clin</source>. <year>2011</year>; <volume>61</volume>: <fpage>69</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.20107" xlink:type="simple">10.3322/caac.20107</ext-link></comment> <object-id pub-id-type="pmid">21296855</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nepple</surname> <given-names>KG</given-names></name>, <name name-style="western"><surname>O'Donnell</surname> <given-names>MA</given-names></name>. <article-title>The optimal management of T1 high-grade bladder cancer</article-title>. <source>Can Urol Assoc J</source>. <year>2009</year>; <volume>3</volume>: <fpage>S188</fpage>–<lpage>192</lpage>. <object-id pub-id-type="pmid">20019983</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alkhateeb</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Neill</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bar-Moshe</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rhijn</surname> <given-names>BV</given-names></name>, <name name-style="western"><surname>Kakiashvili</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Fleshner</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin</article-title>. <source>Urol Ann</source>. <year>2011</year>; <volume>3</volume>: <fpage>119</fpage>–<lpage>126</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4103/0974-7796.84954" xlink:type="simple">10.4103/0974-7796.84954</ext-link></comment> <object-id pub-id-type="pmid">21976923</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dolicanin</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Velickovic</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Djordjevic</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Visnjic</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pesic</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Ristic</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Expression of regulatory proteins and proliferative activity in relation to phenotypic characteristics of upper urothelial carcinoma</article-title>. <source>Vojnosanit Pregl</source>. <year>2011</year>; <volume>68</volume>: <fpage>567</fpage>–<lpage>574</lpage>. <object-id pub-id-type="pmid">21899177</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>da Silva</surname> <given-names>GN</given-names></name>, <name name-style="western"><surname>Evangelista</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>Magalhaes</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Macedo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bufalo</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Sakamoto-Hojo</surname> <given-names>ET</given-names></name>, <etal>et al</etal>. <article-title>Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells</article-title>. <source>Mol Biol Rep</source>. <year>2011</year>; <volume>38</volume>: <fpage>4159</fpage>–<lpage>4170</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11033-010-0536-x" xlink:type="simple">10.1007/s11033-010-0536-x</ext-link></comment> <object-id pub-id-type="pmid">21116856</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Park</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Ahn</surname> <given-names>H</given-names></name>. <article-title>Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?</article-title> <source>Urol Oncol</source>. <year>2013</year>; <volume>31</volume>: <fpage>849</fpage>–<lpage>856</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.urolonc.2011.06.004" xlink:type="simple">10.1016/j.urolonc.2011.06.004</ext-link></comment> <object-id pub-id-type="pmid">21782482</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Rhijn</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Vis</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Bostrom</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Zuiverloon</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Fleshner</surname> <given-names>NE</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer</article-title>. <source>BJU Int</source>. <year>2012</year>; <volume>110</volume>: <fpage>1169</fpage>–<lpage>1176</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1464-410X.2012.10996.x" xlink:type="simple">10.1111/j.1464-410X.2012.10996.x</ext-link></comment> <object-id pub-id-type="pmid">22448597</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cormio</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Tolve</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Annese</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Saracino</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zamparese</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Sanguedolce</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer</article-title>. <source>Anticancer Res</source>. <year>2009</year>; <volume>29</volume>: <fpage>4201</fpage>–<lpage>4204</lpage>. <object-id pub-id-type="pmid">19846973</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Esuvaranathan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Chiong</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Thamboo</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Kamaraj</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mahendran</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha</article-title>. <source>Cancer</source>. <year>2007</year>; <volume>109</volume>: <fpage>1097</fpage>–<lpage>1105</lpage>. <object-id pub-id-type="pmid">17311305</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peyromaure</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Weibing</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sebe</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Verpillat</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Toublanc</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dauge</surname> <given-names>MC</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy</article-title>. <source>Urology</source>. <year>2002</year>; <volume>59</volume>: <fpage>409</fpage>–<lpage>413</lpage>. <object-id pub-id-type="pmid">11880082</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saint</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Le Frere Belda</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Quintela</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hoznek</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Patard</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Bellot</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG)</article-title>. <source>Eur Urol</source>. <year>2004</year>; <volume>45</volume>: <fpage>475</fpage>–<lpage>482</lpage>. <object-id pub-id-type="pmid">15041112</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oh</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Ji</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>DK</given-names></name>, <name name-style="western"><surname>Gong</surname> <given-names>IH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>DS</given-names></name>. <article-title>A six-week course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53</article-title>. <source>Oncology</source>. <year>2010</year>; <volume>79</volume>: <fpage>440</fpage>–<lpage>446</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000327214" xlink:type="simple">10.1159/000327214</ext-link></comment> <object-id pub-id-type="pmid">21487231</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>C</given-names></name>. <article-title>Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers</article-title>. <source>Int J Urol</source>. <year>1997</year>; <volume>4</volume>: <fpage>552</fpage>–<lpage>556</lpage>. <object-id pub-id-type="pmid">9477182</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oderda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ricceri</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Pisano</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Fiorito</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gurioli</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Casetta</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guerin-treated non-muscle-invasive bladder cancer: a prospective study</article-title>. <source>Urol Int</source>. <year>2013</year>; <volume>90</volume>: <fpage>184</fpage>–<lpage>190</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000343431" xlink:type="simple">10.1159/000343431</ext-link></comment> <object-id pub-id-type="pmid">23328160</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopez-Beltran</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Luque</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Alvarez-Kindelan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Quintero</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Merlo</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Carrasco</surname> <given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1)</article-title>. <source>Eur Urol</source>. <year>2004</year>; <volume>45</volume>: <fpage>606</fpage>–<lpage>612</lpage>. <object-id pub-id-type="pmid">15082203</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lacombe</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dalbagni</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>ZF</given-names></name>, <name name-style="western"><surname>Cordon-Cardo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fair</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Herr</surname> <given-names>HW</given-names></name>, <etal>et al</etal>. <article-title>Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome</article-title>. <source>J Clin Oncol</source>. <year>1996</year>; <volume>14</volume>: <fpage>2646</fpage>–<lpage>2652</lpage>. <object-id pub-id-type="pmid">8874323</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Button</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Mokrysz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Nosek</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Flint</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Robinson</surname> <given-names>ES</given-names></name>, <etal>et al</etal>. <article-title>Power failure: why small sample size undermines the reliability of neuroscience</article-title>. <source>Nat Rev Neurosci</source>. <year>2013</year>; <volume>14</volume>: <fpage>365</fpage>–<lpage>376</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrn3475" xlink:type="simple">10.1038/nrn3475</ext-link></comment> <object-id pub-id-type="pmid">23571845</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>H</given-names></name>. <article-title>Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies</article-title>. <source>J Clin Oncol</source>. <year>2011</year>; <volume>29</volume>: <fpage>3775</fpage>–<lpage>3782</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2011.35.7566" xlink:type="simple">10.1200/JCO.2011.35.7566</ext-link></comment> <object-id pub-id-type="pmid">21876081</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mulrow</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gotzsche</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title>. <source>PLoS Med</source>. <year>2009</year>; <volume>6</volume>: <fpage>e1000100</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000100" xlink:type="simple">10.1371/journal.pmed.1000100</ext-link></comment> <object-id pub-id-type="pmid">19621070</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parmar</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Torri</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>L</given-names></name>. <article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title>. <source>Stat Med</source>. <year>1998</year>; <volume>17</volume>: <fpage>2815</fpage>–<lpage>2834</lpage>. <object-id pub-id-type="pmid">9921604</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>; <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>. <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lau</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Antman</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Jimenez-Silva</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kupelnick</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Mosteller</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Chalmers</surname> <given-names>TC</given-names></name>. <article-title>Cumulative meta-analysis of therapeutic trials for myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1992</year>; <volume>327</volume>: <fpage>248</fpage>–<lpage>254</lpage>. <object-id pub-id-type="pmid">1614465</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source>. <year>2002</year>; <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>. <object-id pub-id-type="pmid">12111919</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bax</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ikeda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Fukui</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Yaju</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tsuruta</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Moons</surname> <given-names>KG</given-names></name>. <article-title>More than numbers: the power of graphs in meta-analysis</article-title>. <source>Am J Epidemiol</source>. <year>2009</year>; <volume>169</volume>: <fpage>249</fpage>–<lpage>255</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/aje/kwn340" xlink:type="simple">10.1093/aje/kwn340</ext-link></comment> <object-id pub-id-type="pmid">19064649</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Alcohol drinking and all cancer mortality: a meta-analysis</article-title>. <source>Ann Oncol</source>. <year>2013</year>; <volume>24</volume>: <fpage>807</fpage>–<lpage>816</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mds508" xlink:type="simple">10.1093/annonc/mds508</ext-link></comment> <object-id pub-id-type="pmid">23104725</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Mao</surname> <given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Dietary carrot consumption and the risk of prostate cancer</article-title>. <source>Eur J Nutr</source>. <year>2014</year>; <volume>53</volume>: <fpage>1615</fpage>–<lpage>1623</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00394-014-0667-2" xlink:type="simple">10.1007/s00394-014-0667-2</ext-link></comment> <object-id pub-id-type="pmid">24519559</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duval</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tweedie</surname> <given-names>R</given-names></name>. <article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>. <source>Biometrics</source>. <year>2000</year>; <volume>56</volume>: <fpage>455</fpage>–<lpage>463</lpage>. <object-id pub-id-type="pmid">10877304</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Rhijn</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Burger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lotan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Solsona</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Stief</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Sylvester</surname> <given-names>RJ</given-names></name>, <etal>et al</etal>. <article-title>Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy</article-title>. <source>Eur Urol</source>. <year>2009</year>; <volume>56</volume>: <fpage>430</fpage>–<lpage>442</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2009.06.028" xlink:type="simple">10.1016/j.eururo.2009.06.028</ext-link></comment> <object-id pub-id-type="pmid">19576682</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Resnick</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Bassett</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Clark</surname> <given-names>PE</given-names></name>. <article-title>Management of superficial and muscle-invasive urothelial cancers of the bladder</article-title>. <source>Curr Opin Oncol</source>. <year>2013</year>; <volume>25</volume>: <fpage>281</fpage>–<lpage>288</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CCO.0b013e32835eb583" xlink:type="simple">10.1097/CCO.0b013e32835eb583</ext-link></comment> <object-id pub-id-type="pmid">23425709</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Oosterlinck</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Konety</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gudjonsson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pruthi</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder</article-title>. <source>Eur Urol</source>. <year>2013</year>; <volume>63</volume>: <fpage>36</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2012.08.061" xlink:type="simple">10.1016/j.eururo.2012.08.061</ext-link></comment> <object-id pub-id-type="pmid">22981672</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Babjuk</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Burger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zigeuner</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Shariat</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>van Rhijn</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Comperat</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013</article-title>. <source>Eur Urol</source>. <year>2013</year>; <volume>64</volume>: <fpage>639</fpage>–<lpage>653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2013.06.003" xlink:type="simple">10.1016/j.eururo.2013.06.003</ext-link></comment> <object-id pub-id-type="pmid">23827737</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xylinas</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kent</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kluth</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Pycha</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Comploj</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Svatek</surname> <given-names>RS</given-names></name>, <etal>et al</etal>. <article-title>Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder</article-title>. <source>Br J Cancer</source>. <year>2013</year>; <volume>109</volume>: <fpage>1460</fpage>–<lpage>1466</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.2013.372" xlink:type="simple">10.1038/bjc.2013.372</ext-link></comment> <object-id pub-id-type="pmid">23982601</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sylvester</surname> <given-names>RJ</given-names></name>. <article-title>How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?</article-title> <source>Eur Urol</source>. <year>2011</year>; <volume>60</volume>: <fpage>431</fpage>–<lpage>433</lpage>; discussion 433–434. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2011.06.001" xlink:type="simple">10.1016/j.eururo.2011.06.001</ext-link></comment> <object-id pub-id-type="pmid">21680084</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fridman</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Lowe</surname> <given-names>SW</given-names></name>. <article-title>Control of apoptosis by p53</article-title>. <source>Oncogene</source>. <year>2003</year>; <volume>22</volume>: <fpage>9030</fpage>–<lpage>9040</lpage>. <object-id pub-id-type="pmid">14663481</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muller</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Vousden</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Norman</surname> <given-names>JC</given-names></name>. <article-title>p53 and its mutants in tumor cell migration and invasion</article-title>. <source>J Cell Biol</source>. <year>2011</year>; <volume>192</volume>: <fpage>209</fpage>–<lpage>218</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.201009059" xlink:type="simple">10.1083/jcb.201009059</ext-link></comment> <object-id pub-id-type="pmid">21263025</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gontero</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Casetta</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Zitella</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ballario</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pacchioni</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Magnani</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder</article-title>. <source>Eur Urol</source>. <year>2000</year>; <volume>38</volume>: <fpage>287</fpage>–<lpage>296</lpage>. <object-id pub-id-type="pmid">10940702</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakopoulou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Vourlakou</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Zervas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tzonou</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gakiopoulou</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Dimopoulos</surname> <given-names>MA</given-names></name>. <article-title>The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates</article-title>. <source>Hum Pathol</source>. <year>1998</year>; <volume>29</volume>: <fpage>146</fpage>–<lpage>154</lpage>. <object-id pub-id-type="pmid">9490274</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bernardini</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Adessi</surname> <given-names>GL</given-names></name>, <name name-style="western"><surname>Billerey</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chezy</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Carbillet</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Bittard</surname> <given-names>H</given-names></name>. <article-title>Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas</article-title>. <source>J Urol</source>. <year>1999</year>; <volume>162</volume>: <fpage>1496</fpage>–<lpage>1501</lpage>. <object-id pub-id-type="pmid">10492244</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>ZH</given-names></name>, <name name-style="western"><surname>Bao</surname> <given-names>ED</given-names></name>. <article-title>Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk</article-title>. <source>Mol Biol Rep</source>. <year>2013</year>; <volume>40</volume>: <fpage>2389</fpage>–<lpage>2395</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11033-012-2319-z" xlink:type="simple">10.1007/s11033-012-2319-z</ext-link></comment> <object-id pub-id-type="pmid">23184052</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Nie</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Luo</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Association of p53 Arg72Pro polymorphism with bladder cancer: a meta-analysis</article-title>. <source>Gene</source>. <year>2013</year>; <volume>512</volume>: <fpage>408</fpage>–<lpage>413</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.gene.2012.09.085" xlink:type="simple">10.1016/j.gene.2012.09.085</ext-link></comment> <object-id pub-id-type="pmid">23073555</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>ZC</given-names></name>, <name name-style="western"><surname>Zou</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>XE</given-names></name>. <article-title>P53 Arg72Pro polymorphism and bladder cancer risk—meta-analysis evidence for a link in Asians but not Caucasians</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2012</year>; <volume>13</volume>: <fpage>2349</fpage>–<lpage>2354</lpage>. <object-id pub-id-type="pmid">22901221</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jiang</surname> <given-names>DK</given-names></name>, <name name-style="western"><surname>Ren</surname> <given-names>WH</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>WZ</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>L</given-names></name>. <article-title>Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk</article-title>. <source>Urology</source>. <year>2010</year>; <volume>76</volume>: <fpage>765 e761</fpage>–<lpage>767</lpage>.</mixed-citation></ref>
<ref id="pone.0119476.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>DB</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>F</given-names></name>. <article-title>Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer</article-title>. <source>Genet Mol Res</source>. <year>2010</year>; <volume>9</volume>: <fpage>1599</fpage>–<lpage>1605</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4238/vol9-3gmr882" xlink:type="simple">10.4238/vol9-3gmr882</ext-link></comment> <object-id pub-id-type="pmid">20730711</object-id></mixed-citation></ref>
<ref id="pone.0119476.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Malats</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bustos</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nascimento</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Rivas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Puente</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>P53 as a prognostic marker for bladder cancer: a meta-analysis and review</article-title>. <source>Lancet Oncol</source>. <year>2005</year>; <volume>6</volume>: <fpage>678</fpage>–<lpage>686</lpage>. <object-id pub-id-type="pmid">16129368</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>